BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma.
Adam R WolfePriyanka ChablaniMichael R SiedowEric D MillerSteve WalstonKari L KendraEvan WuthrickTerence M WilliamsPublished in: Radiation oncology (London, England) (2021)
Stage III melanoma patients with BRAF mutation treated with adjuvant RT had > 4 times increased risk of local recurrence or regional lymph node recurrence. These results could be useful for adjuvant RT consideration in lymph node positive melanoma patients and supports other data that BRAF mutation confers radiation resistance.
Keyphrases
- lymph node
- radiation therapy
- end stage renal disease
- early stage
- newly diagnosed
- metastatic colorectal cancer
- neoadjuvant chemotherapy
- skin cancer
- ejection fraction
- chronic kidney disease
- wild type
- sentinel lymph node
- peritoneal dialysis
- prognostic factors
- free survival
- squamous cell carcinoma
- big data
- machine learning
- deep learning
- artificial intelligence
- rectal cancer